Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

CORIMUNO-19, 2020
 
NCT04331808
RCTtocilizumab standard of careCOVID-19 mild to moderatesome concern
64/67 inconclusive
    EMPACTA, 2020
     
    NCT04372186
    RCTtocilizumab placeboCOVID-19 mild to moderatesome concern
    259/129 conclusif
    • demonstrated 44 % decrease in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 45 % decrease in clinical deterioration with a moderate degree of certainty due to some concern in risk of bias
    Capra, 2020 OBStocilizumab controlCOVID-19 mild to moderatecritical
    62/23 suggested
    • suggested 96 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).